Special feature: pharmacotherapy in personality disorders

Area of Science:

• Psychiatry
• Clinical Pharmacology
• Psychobiology

Background:

• Epidemiological and psychobiological studies suggest psychopharmacology's potential in treating personality disorders.
• Psychotropic drugs may benefit personality disorders with strong links to Axis I disorders, such as schizotypal personality disorder and schizophrenia.
• These medications can also target specific psychopathological symptom clusters across various disorders.

Purpose of the Study:

• To review clinical pharmacological studies on the efficacy of psychotropic drugs for personality disorders.
• To provide guidelines for the use of pharmacotherapy in personality disorder treatment.
• To examine the role of psychotropic drugs in managing symptomatic crises and psychiatric comorbidity.

Main Methods:

• Review of clinical pharmacological studies.
• Analysis of treatment outcomes for Cluster A, B, and C personality disorders.
• Consideration of psychotropic drug effects on symptom clusters and comorbidities.

Main Results:

• Pharmacotherapy is indicated for personality disorders closely associated with Axis I disorders.
• Psychotropic drugs can influence symptom clusters like cognitive-perceptual organization, impulsivity, and affective instability.
• Treatment may be short-term, but long-term therapy can be promising in some cases.

Conclusions:

• Psychotropic drug use in personality disorders is promising, particularly for those with Axis I comorbidities.
• Consideration of pharmacotherapy is advised during symptomatic crises, especially with secondary psychiatric comorbidity.
• Effective pharmacotherapy necessitates a supportive therapeutic relationship between physician and patient.